JLK targets AI stroke solution market in U.S.

Kim Dong-min, CEO of JLK, is explaining the AI system for stroke diagnosis. (JLK)

JLK, South Korea’s first publicly listed medical artificial intelligence (AI) company, has set its sight on entering the U.S. market with its stroke diagnosis solutions.

“Our AI-driven diagnostic solutions are enhancing the accuracy and speed of stroke diagnosis, particularly in hospitals that lack dedicated stroke specialists,” said JLK CEO Kim Dong-min, in a recent interview with Maeil Business Newspaper.

Kim explained that traditional diagnostic methods rely on physicians manually interpreting CT and MRI scans to identify lesions and other key stroke-related data, such as lesion location, volume, and cause.

“Now, AI technology not only speeds up this process but also improves precision,” Kim said.

He highlighted that AI solutions are especially useful in emergency rooms of small and medium-sized hospitals, where timely responses are critical.

“AI enables quicker responses in critical situations, leading to better outcomes for stroke patients,” Kim said.

He emphasized that stroke is a global concern, affecting both developed and developing nations, but diagnostic capabilities vary widely.

“AI solutions can analyze CT and MRI images anywhere in the world, which will help save countless lives.”

JLK is now looking to expand its AI stroke diagnostic solutions in North America, which accounts for over 40 percent of the global market.

The company aims to compete with established players like RapidAI in the U.S. and Viz.AI in Israel. As part of its U.S. expansion strategy, JLK has already taken steps toward gaining regulatory approval.

In June, it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AI-based prostate cancer diagnostic solution.

Kim said that JLK plans to submit applications for three additional AI solutions by the end of the year, with hopes of securing at least two or three more FDA approvals.

These approvals would pave the way for the company to firmly establish its presence in the U.S. market.

JLK will be hosting a seminar in Seoul next month, where world-renowned stroke experts will gather to discuss the future of AI in stroke diagnosis.